DCG-78105-36349
3 vaccinations
8 coded responses
32 check-ins
8 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 56-60
- ZIP prefix
- 550 / MN
- Registered
- 2021-01-11
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-11
Registered in v-safe
-
2021-01-11
Dose 1 — Moderna
- 2021-01-11
- 2021-01-12
- 2021-01-13
- 2021-01-14
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-18
- 2021-01-25
- 2021-02-01
-
2021-02-04
Dose 2 — Moderna
- 2021-02-04
- 2021-02-05
- 2021-02-07
- 2021-02-08
- 2021-02-09
- 2021-02-10
- 2021-02-11
- 2021-02-18
- 2021-02-25
- 2021-03-04
- 2021-03-11
- 2021-03-18
- 2021-05-06
-
2021-08-05
Survey response — 6 months, dose 2MedDRA: Pneumonia, Renal cell carcinoma — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Diagnosed with Mycobacteria lung infection and renal cell carcinomaMedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-10-20
Dose 3 — Moderna
-
2021-10-24
Survey response — days 1–6 daily, dose 3MedDRA: Metastatic renal cell carcinoma, Oropharyngeal pain, Stomatitis — Feeling: Good · Be unable to work or attend schoolFree text: I have sore throat and mouth sores but believe them to be side effects from cancer med I am taking for mRCC diagnosed in August 2021MedDRA releases: 2024-11 · check-in free text available
-
2021-10-25
Survey response — days 1–6 daily, dose 3MedDRA: Renal cell carcinoma — Feeling: Good · Be unable to work or attend schoolFree text: Diagnosed in August with renal cell carcinomaMedDRA releases: 2024-11 · check-in free text available
-
2021-10-26
Survey response — days 1–6 daily, dose 3MedDRA: Oropharyngeal pain, Renal cell carcinoma — Feeling: GoodFree text: Sore throat but thinking it is side effect of Lenvima med being taken for recently diagnosed Renal Cell CarcinomaMedDRA releases: 2024-11 · check-in free text available
-
2021-10-29
Survey response — day 7, dose 3MedDRA: Pre-existing disease — Feeling: Good · Be unable to work or attend schoolFree text: Received Keytruda infusion today for renal cancer treatmentMedDRA releases: 2024-11 · check-in free text available
-
2021-11-03
Survey response — day 14, dose 3MedDRA: Blood thyroid stimulating hormone increased, Pre-existing disease — Feeling: Good · Be unable to work or attend schoolFree text: Elevated TSH, most probably due to Lenvima med to RCC treatmentMedDRA releases: 2024-11 · check-in free text available
-
2021-11-12
Survey response — day 21, dose 3MedDRA: Headache — Feeling: FairFree text: Headache for last 8 daysMedDRA releases: 2024-11 · check-in free text available
-
2021-11-17
Survey response — day 28, dose 3MedDRA: Headache, Myalgia, Pain — Feeling: Fair · Be unable to work or attend schoolFree text: Muscle and body aches. Ongoing headache for two weeks Most likely side effects of cancer treatment medsMedDRA releases: 2024-11 · check-in free text available
- 2021-11-24
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-11 | Moderna | |
| 2 | 2021-02-04 | Moderna | |
| 3 | 2021-10-20 | Moderna | No |
Free text
Release 9 — 6 months, dose 2
Symptoms: Diagnosed with Mycobacteria lung infection and renal cell carcinoma
Release 10 — days 1–6 daily, dose 3
Systemic reaction (other): I have sore throat and mouth sores but believe them to be side effects from cancer med I am taking for mRCC diagnosed in August 2021
Systemic reaction (other): Diagnosed in August with renal cell carcinoma
Systemic reaction (other): Sore throat but thinking it is side effect of Lenvima med being taken for recently diagnosed Renal Cell Carcinoma
Release 10 — day 7, dose 3
Systemic reaction (other): Received Keytruda infusion today for renal cancer treatment
Release 10 — day 14, dose 3
Symptoms: Elevated TSH, most probably due to Lenvima med to RCC treatment
Release 10 — day 21, dose 3
Symptoms: Headache for last 8 days
Release 10 — day 28, dose 3
Symptoms: Muscle and body aches. Ongoing headache for two weeks Most likely side effects of cancer treatment meds
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Blood thyroid stimulating hormone increased | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Myalgia | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Pneumonia | ✓ | · | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
| SD | Renal cell carcinoma | ✓ | · | ✓ |
| SRO | Metastatic renal cell carcinoma | · | · | ✓ |
| SRO | Oropharyngeal pain | · | · | ✓ |
| SRO | Pre-existing disease | · | · | ✓ |
| SRO | Renal cell carcinoma | · | · | ✓ |
| SRO | Stomatitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release